Fox Chase Cancer Center News

PHILADELPHIA (April 9, 2021)— During a poster session at this year’s American Association for Cancer Research (AACR) Annual Meeting Part 1, researchers at Fox Chase Cancer Center will present findings from a recent study on predicting therapy response in locally advanced rectal cancer patients.

PHILADELPHIA (April 8, 2021)—A study from researchers at Fox Chase Cancer Center has shown that while complication rates differ among methods of reconstructive breast surgery, both implants and autologous methods that use a patient’s own tissue are safe options.

PHILADELPHIA (April 7, 2021)—In a recent study, researchers at Fox Chase Cancer Center identified several factors that may accurately predict the presence of malignant cells in pancreatic cancer patients who undergo a peritoneal washing.

PHILADELPHIA (April 7, 2021)—Fox Chase Cancer Center was recently awarded Tobacco Treatment Program Supplements from the National Cancer Institute to support the expansion of current services for patients who use tobacco. 

PHILADELPHIA (MARCH 30, 2021)—There’s more and more evidence that genes associated with one type of cancer may increase risk for other cancers as well. Now a study by Fox Chase Cancer Center scientists quantifies new risks for pancreatic, prostate, gastric, and other cancer in a gene previously linked to breast cancer.

PHILADELPHIA (March 29, 2021)—Sameer Patel, MD, FACS, chief of the Division of Plastic and Reconstructive Surgery in the Department of Surgical Oncology at Fox Chase Cancer Center and the Temple University Health System, has co-authored a new textbook, “Cosmetic Breast Surgery.”

PHILADELPHIA (March 29, 2021)—Sameer Patel, MD, FACS, chief of the Division of Plastic and Reconstructive Surgery in the Department of Surgical Oncology at Fox Chase Cancer Center and the Temple University Health System, has co-authored a new textbook, “Cosmetic Breast Surgery.”

PHILADELPHIA (March 26, 2021)—In a recently published study, researchers at Fox Chase Cancer Center found that reprogramming cancer-associated fibroblasts that define tumor progression in pancreatic ductal adenocarcinoma could potentially restore the fibroblasts’ ability to work against tumors. Further development of the findings could have applications in the treatment of cancer.